Quantitative Determination of Epa and Dha in Fish Oil Capsules for Cardiovascular Disease Therapy in Indonesia by Gc-Ms

Background The consumption of EPA (Eicosapentaenoic acid), and DHA (docosahexaenoic from fish oil, in the long run, has been observed to have a positive impact on patients with coronary heart disease. Fish oil products, so much content are available, very variable prices. Therefore, as therapy be used for long-term treatment, cost factor is considered. Design methods This study analyzed DHA, using GC-MS. sample was that lowest price (Product A1), highest A2). Furthermore, macroscopic analysis performed, by observing physical form including organoleptic qualitative tests, reading fragments identified DHA. Results Clinical trials were conducted (about 46 people), risk factors dyslipidemia. Product A1 showed at t R= 15.574 min (relative%= 88.49%, similarity= 95%), 21.714 88.92%, 93%). A2 28.719 22.58%, 89%), 32.327 22.87%, 90%), which meant both had contents, accordance their labels. Both products confirmed reduce total cholesterol 4weeks (p=0.000, p= 0.000), no significant difference effectiveness (p=0.652). Conclusion results contents respective However, product having percentage relatively higher than brand, equally effective.